Natco Pharma launches Lymfuda for leukemia

By Lisa Kerner

Erie, Pa., March 7 - Natco Pharma Ltd. launched its Lymfuda (fludarabine) 10 mg tablets, an alkylating agent useful in the treatment of chronic lymphocytic leukemia.

Chronic lymphocytic leukemia is characterized by a large number of cancerous mature lymphocytic and enlarged lymph nodes, according to a company news release.

Natco, based in India, manufactures a range of branded and generic dosage forms, bulk actives and intermediates.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.